PURPOSE: This is a phase II study of perillyl alcohol in the treatment of patients with metastatic colorectal carcinoma. The primary endpoint is time to progression. Secondary objectives are to evaluate objective response rate and toxicity. PATIENTS AND METHODS: Eligible patients had metastatic adenocarcinoma of the colon or rectum. Patients received perillyl alcohol orally at a dose of 1200 mg/m2. Dose escalation to 1,600 mg/m2 was allowed. RESULTS: Twenty-seven patients were enrolled. The median time to progression was 1.8 months (range 1 to 3 mo). Four patients received less than one cycle and were not evaluable for response. Of the remaining 23, all had progressive disease. There were no complete or partial responses. Toxicity was relatively mild, with fatigue, nausea and anemia predominating. Three patients withdrew from therapy for toxicity (grade 3 belching, bloating; grade 2 nausea, fatigue, vomiting, anorexia and increase perspiration; grade 1 anorexia). DISCUSSION: Despite preclinical evidence of anticancer activity, oral perillyl alcohol administered at this dose and formulation does not appear to have clinical antitumor activity when used for patients with advanced colorectal carcinoma.
PURPOSE: This is a phase II study of perillyl alcohol in the treatment of patients with metastatic colorectal carcinoma. The primary endpoint is time to progression. Secondary objectives are to evaluate objective response rate and toxicity. PATIENTS AND METHODS: Eligible patients had metastatic adenocarcinoma of the colon or rectum. Patients received perillyl alcohol orally at a dose of 1200 mg/m2. Dose escalation to 1,600 mg/m2 was allowed. RESULTS: Twenty-seven patients were enrolled. The median time to progression was 1.8 months (range 1 to 3 mo). Four patients received less than one cycle and were not evaluable for response. Of the remaining 23, all had progressive disease. There were no complete or partial responses. Toxicity was relatively mild, with fatigue, nausea and anemia predominating. Three patients withdrew from therapy for toxicity (grade 3 belching, bloating; grade 2 nausea, fatigue, vomiting, anorexia and increase perspiration; grade 1 anorexia). DISCUSSION: Despite preclinical evidence of anticancer activity, oral perillyl alcohol administered at this dose and formulation does not appear to have clinical antitumor activity when used for patients with advanced colorectal carcinoma.
Authors: F Maindrault-Goebel; C Louvet; T André; E Carola; J P Lotz; J L Molitor; M L Garcia; V Gilles-Amar; V Izrael; M Krulik; A de Gramont Journal: Eur J Cancer Date: 1999-09 Impact factor: 9.162
Authors: S Giacchetti; B Perpoint; R Zidani; N Le Bail; R Faggiuolo; C Focan; P Chollet; J F Llory; Y Letourneau; B Coudert; F Bertheaut-Cvitkovic; D Larregain-Fournier; A Le Rol; S Walter; R Adam; J L Misset; F Lévi Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques Journal: Lancet Date: 1998-10-31 Impact factor: 79.321
Authors: Howard H Bailey; Donna Levy; Linda S Harris; Julian C Schink; Francine Foss; Peter Beatty; Scott Wadler Journal: Gynecol Oncol Date: 2002-06 Impact factor: 5.482
Authors: Juliana de Saldanha da Gama Fischer; Paulo Costa Carvalho; Clovis Orlando da Fonseca; Lujian Liao; Wim M Degrave; Maria da Gloria da Costa Carvalho; John R Yates; Gilberto B Domont Journal: J Proteome Res Date: 2010-09-27 Impact factor: 4.466
Authors: Glenn Liu; Jill Kolesar; Douglas G McNeel; Catherine Leith; Kathy Schell; Jens Eickhoff; Fred Lee; Anne Traynor; Rebecca Marnocha; Dona Alberti; James Zwiebel; George Wilding Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Juliana de Saldanha da Gama Fischer; Lujian Liao; Paulo C Carvalho; Valmir C Barbosa; Gilberto B Domont; Maria da Gloria da Costa Carvalho; John R Yates Journal: J Proteomics Date: 2010-01-18 Impact factor: 4.044
Authors: Steven P Stratton; David S Alberts; Janine G Einspahr; Paul M Sagerman; James A Warneke; Clara Curiel-Lewandrowski; Paul B Myrdal; Kelly L Karlage; Brian J Nickoloff; Chris Brooks; Kathylynn Saboda; Michael L Yozwiak; Mary F Krutzsch; Chengcheng Hu; Maria Lluria-Prevatt; Zigang Dong; G Timothy Bowden; Peter H Bartels Journal: Cancer Prev Res (Phila) Date: 2010-01-26
Authors: Nitin S Nandurkar; Jianjun Zhang; Qing Ye; Larissa V Ponomareva; Qing-Bai She; Jon S Thorson Journal: J Med Chem Date: 2014-08-25 Impact factor: 7.446